In a retrospective analysis, investigators in Finland studied the risk factors for intensive care unit (ICU) admission among patients with MG. Patients with MG who needed intensive care tended to be ...

Kiran Bhavaraju-Sanka, MD, and Beth Stein, MD, focus on the best and most effective methods of engaging patients who have myasthenia gravis throughout their journey. Bhavaraju-Sanka is the John H.

KYV-101 demonstrated significant efficacy in reducing MG-ADL and QMG scores in gMG patients, with rapid and sustained effects ...

Energy, exercise, family time and even a job—those are the real-life costs of myasthenia gravis (MG) highlighted in Argenx’s new docuseries about the autoimmune disorder. The three films focus on ...

Myasthenia gravis updates from AANEM 2025 include efficacy data for efgartigimod, telitacicept, and gefurulimab, plus interim ...

The ongoing EPIC clinical trial is the first randomized head-to-head comparison of two neonatal Fc receptor (FcRn)-targeting treatments for generalized myasthenia gravis (gMG) in adults.

Dr Katherine Ruzhansky reviews therapeutic advances that emphasize careful patient selection and individualized combination ...

Please provide your email address to receive an email when new articles are posted on . Nearly half of individuals in a study about activities of daily living among more than 1,000 patients with ...

Please provide your email address to receive an email when new articles are posted on . Efgartigimod, a human IgG1 antibody designed to decrease pathogenic IgG autoantibody levels, demonstrated ...

FOR many years it has been recognized that myasthenia gravis is associated, in a high percentage of cases, with structural abnormalities of the thymus. 1 Many patients, especially the younger ones, ...

Terri Justick struggles with one of the most underrepresented diseases in the world, but by educating the public about myasthenia gravis, she discovers hope for finding a cure. The Philadelphia native ...

A new Yale-led study helps explain why some myasthenia gravis (MG) patients relapse after initially responding to a drug called rituximab, commonly used to treat the incurable autoimmune disease ...